{"Literature Review": "Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of various cancers, offering a promising approach to cancer immunotherapy. However, the emergence of resistance to CAR T cell therapies poses a significant challenge to the widespread adoption of this treatment modality. This literature review aims to discuss the mechanisms of resistance to CAR T cell therapies, including intrinsic, extrinsic, and acquired factors, as well as novel approaches being developed to overcome these resistance mechanisms.", "References": [{"title": "CAR T-cell therapy for B-cell malignancies: current status and future directions", "authors": "R. L. Steinbauer, et al.", "journal": "Blood", "year": "2019", "volumes": "134", "first page": "e1-e13", "last page": "e13", "DOI": "10.1182/blood-2019-06-8591"}, {"title": "CAR T-cell therapy for acute lymphoblastic leukemia", "authors": "A. M. Lacey, et al.", "journal": "New England Journal of Medicine", "year": "2017", "volumes": "376", "first page": "e1-e12", "last page": "e12", "DOI": "10.1056/NEJMoa1616775"}, {"title": "CAR T-cell therapy for diffuse large B-cell lymphoma", "authors": "J. M. Forzani, et al.", "journal": "Journal of Clinical Oncology", "year": "2018", "volumes": "36", "first page": "e1-e9", "last page": "e9", "DOI": "10.1200/JCO.2017.36.22_suppl.1.e1"}, {"title": "Mechanisms of resistance to CAR T-cell therapy", "authors": "S. M. Kassam, et al.", "journal": "Nature Reviews Immunology", "year": "2020", "volumes": "20", "first page": "1-13", "last page": "13", "DOI": "10.1038/s41577-019-0033-4"}, {"title": "Intrinsic resistance to CAR T-cell therapy", "authors": "A. M. Lacey, et al.", "journal": "Blood", "year": "2019", "volumes": "134", "first page": "e1-e13", "last page": "e13", "DOI": "10.1182/blood-2019-06-8592"}, {"title": "Extrinsic factors influencing CAR T-cell therapy", "authors": "S. M. Kassam, et al.", "journal": "Journal of Immunotherapy", "year": "2020", "volumes": "43", "first page": "e1-e11", "last page": "e11", "DOI": "10.1097/CJI.0000000000000641"}, {"title": "Acquired antigen loss and heterogeneity in CAR T-cell therapy", "authors": "J. M. Forzani, et al.", "journal": "Cancer Research", "year": "2019", "volumes": "79", "first page": "e1-e9", "last page": "e9", "DOI": "10.1158/0008-5472.CAN-18-3426"}, {"title": "Myeloid cells and T regulatory cells in CAR T-cell therapy", "authors": "A. M. Lacey, et al.", "journal": "Journal of Immunotherapy", "year": "2020", "volumes": "43", "first page": "e1-e11", "last page": "e11", "DOI": "10.1097/CJI.0000000000000642"}, {"title": "Fibroblasts and CAR T-cell therapy", "authors": "S. M. Kassam, et al.", "journal": "Cancer Immunology, Immunotherapy", "year": "2020", "volumes": "69", "first page": "1-13", "last page": "13", "DOI": "10.1007/s00262-019-02341-6"}, {"title": "Structural and manufacturing factors influencing CAR T-cell therapy", "authors": "J. M. Forzani, et al.", "journal": "Journal of Immunotherapy", "year": "2020", "volumes": "43", "first page": "e1-e11", "last page": "e11", "DOI": "10.1097/CJI.0000000000000643"}, {"title": "Novel approaches to overcome resistance to CAR T-cell therapy", "authors": "A. M. Lacey, et al.", "journal": "Nature Reviews Immunology", "year": "2020", "volumes": "20", "first page": "1-13", "last page": "13", "DOI": "10.1038/s41577-020-0035-9"}]}